ReviewWorld journal of gastroenterology2008
Strategy for treatment of nonerosive reflux disease in Asia.
Review in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.World journal of gastroenterology · 2014Pooled it
- A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.Journal of gastroenterology · 2014Trial
- Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.BMC gastroenterology · 2014Trial
- Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.Journal of gastroenterology · 2012Trial
- Randomized Controlled Trial Comparing the Efficacy of Sustained-Release Formula of Mosapride-Plus-Esomeprazole Combination Therapy to Esomeprazole Monotherapy in Patients with Gastroesophageal Reflux Disease.Journal of clinical medicine · 2022Article
- Efficacy and Safety of Traditional Chinese Medicine on Nonerosive Reflux Disease: A Meta-Analysis of Randomized Controlled Trials.Evidence-based complementary and alternative medicine : eCAM · 2018Review
- Expression of Serum Exosomal and Esophageal MicroRNA in Rat Reflux Esophagitis.International journal of molecular sciences · 2017Article
- Omeprazole-Domperidone Fixed Dose Combination vs Omeprazole Monotherapy: A Phase 4, Open-Label, Comparative, Parallel Randomized Controlled Study in Mild to Moderate Gastroesophageal Reflux Disease.Clinical medicine insights. Gastroenterology · 2017Article
- Article
- Anxiety and depression in patients with gastroesophageal reflux disease and their effect on quality of life.World journal of gastroenterology · 2015Article
- Clinical application of kampo medicine (rikkunshito) for common and/or intractable symptoms of the gastrointestinal tract.Frontiers in pharmacology · 2015Article
- Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease.World journal of gastroenterology · 2013Article
- Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application.Journal of gastroenterology · 2013Review
- Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan.PloS one · 2013Article
- Effects of Rikkunshito (TJ-43) on Esophageal Motor Function and Gastroesophageal Reflux.Journal of neurogastroenterology and motility · 2012Article
- Detection of gastroesophageal reflux esophagitis using 2-fluoro-2-deoxy-d-glucose positron emission tomography.TheScientificWorldJournal · 2012Article
- Differences in clinical characteristics between patients with non-erosive reflux disease and erosive esophagitis in Korea.Journal of Korean medical science · 2010Article
- Rikkunshito, a traditional Japanese medicine, may relieve abdominal symptoms in rats with experimental esophagitis by improving the barrier function of epithelial cells in esophageal mucosa.Journal of gastroenterology · 2010Article
- Gastro-esophageal reflux disease: the recent trend in Japan.Clinical journal of gastroenterology · 2008Article
- A Multicenter, Randomized, Open-Label Trial: Efficacy of Once-Daily Versus Twice-Daily Double-Dose Rabeprazole on Refractory Gastroesophageal Reflux Disease-Related Symptoms and Quality of Life.Current therapeutic research, clinical and experimentalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The paper is to review the clinical and pathophysiologic differences between of nonerosive reflux disease (NERD) and reflux esophagitis (RE), and to propose a treatment strategy for NERD, especially for patients in Asia. A Medline search was performed regarding the clinical and pathophysiologic differences between NERD and RE, and treatment of NERD and RE. The characteristics of NERD patients in Asia are as follows: (1) high proportion of female patients, (2) low frequency of hiatal hernia, (3) high frequency of H pylori infection, (4) severe glandular atrophy of the gastric mucosa, and (5) frequent resistance to proton pump inhibitor (PPI) therapy. In Asian NERD patients, exposure of the esophagus to acid is not increased, and esophageal motility is normal. These characteristics are similar to those of patients in Western countries. Our recommended first-choice treatment is administration of PPI in combination with a prokinetic agent. However, at present, because there is limited evidence regarding effective treatments for NERD, it is best to try several different treatment strategies to find the best treatment for each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.